The proposed $16 billion valuation represents an enormous jump from the $10.9 billion valuation Oura received last September when it closed an $875 million Series E round. That funding round attracted backing from Fidelity, ICONIQ, Whale Rock, and Atreides, joining earlier investors like Dexcom, The Chernin Group, Forerunner Ventures, Coatue, and Temasek. The aggressive valuation increase reflects the company’s rapid expansion and growing mainstream appeal beyond its original niche market.

Oura announced in May that it had filed confidentially for an IPO, setting the stage for this upcoming public debut. Chief Executive Officer Tom Hale recently disclosed the company’s impressive revenue trajectory, revealing it generated $500 million in revenue in 2024 and roughly $1 billion in 2025. The company expects to generate close to $2 billion in revenue in 2026, driven by international expansion and heavily integrated artificial intelligence coaching features, though detailed financials will become available once its S-1 filing goes public.

From Biohacking Niche to Mainstream Health Brand

The wearable device has undergone a significant transformation from its origins as a niche biohacking tool for tech executives. Oura has successfully evolved into a mainstream sleep-and-recovery brand, shipping over 5.5 million units since its inception across global markets. The more than 900-person company recently pushed deeper into preventative healthcare by introducing an AI chatbot alongside glucose monitoring and blood pressure research capabilities.

This strategic pivot mirrors moves made by competitors in the increasingly crowded wearables space. The company positions itself at the intersection of consumer health technology and preventative medicine, targeting users interested in comprehensive wellness tracking beyond simple step counting. Oura’s expansion into broader health metrics reflects the industry’s shift toward more sophisticated biometric monitoring and personalized health insights powered by artificial intelligence.

Fierce Competition in the Wearables Market

The hardware sector has grown increasingly crowded as major tech players and specialized startups compete for market share. Samsung launched the Galaxy Ring two years ago to capture the Android ecosystem, bringing the tech giant’s resources and distribution network into direct competition with Oura’s offering. The move signaled that smart rings had matured from experimental gadgets into viable consumer products worth investment from major manufacturers.

Oura’s most direct rival may be Whoop, the fitness band maker that has undergone its own reinvention in recent years. Once positioned as a performance tool for elite athletes and young men, Whoop spent the past year courting a much broader audience by layering in hormone tracking and blood-panel testing for perimenopause and thyroid health. The strategic pivot drove Whoop’s own valuation up to $10 billion back in March, demonstrating investor appetite for wearables that address comprehensive health concerns beyond athletic performance.

Legal Challenges Cast Shadow Over IPO Plans

Not all of Oura’s recent attention has been positive, as legal challenges threaten to complicate the company’s public market debut. A proposed class action lawsuit filed last week in San Francisco accuses Oura of misleading consumers about the accuracy of its sleep tracking features. The complaint alleges the company claims capabilities that exceed what its hardware can actually measure, creating potential liability issues ahead of increased public scrutiny that accompanies going public.

“Among other complaints in the filing, Oura is accused of not just claiming to measure a heartbeat or a temperature, but the exact stage of sleep the wearer is in-which in reality requires electrodes in the scalp and sensors on the eyes, as only a hospital or other clinical setting can do,” according to the lawsuit filing.

In a statement to TechCrunch sent over the weekend, an Oura spokesperson pushed back against claims in the suit, indicating the company plans to defend against them in the appropriate legal forum. The spokesperson emphasized that while Oura Ring is not a medical device or a substitute for a clinical sleep study, Oura’s sleep staging has been validated and compared favorably in multiple studies. The legal dispute highlights ongoing tensions around consumer health technology accuracy claims and regulatory standards for wellness devices that increasingly blur the line between consumer gadgets and medical equipment.

High-Stakes Market Entry

The timing of Oura’s IPO reflects both opportunity and risk in the current market environment. The company enters public markets at a moment when investor enthusiasm for health technology remains strong but scrutiny of profitability and unit economics has intensified. Oura’s ability to demonstrate sustainable revenue growth toward the $2 billion target will prove critical in justifying its premium valuation and attracting institutional investors beyond its existing venture backers.

The significant stock sale by existing investors signals both confidence in the company’s long-term prospects and a desire to realize returns after years of private market growth. How public market investors value Oura compared to its venture-backed peers will provide important signals about the broader wearables sector and investor appetite for hardware companies with recurring revenue models. The September timeline puts Oura ahead of potential competitors eyeing similar public market debuts, potentially allowing it to capture investor attention before market conditions shift.

The post Oura Plans September IPO Targeting $16 Billion Valuation After Rapid Growth appeared first on The Daily Update.

Elon Musk is preparing to launch the largest IPO ever with his space exploration and satellite company, SpaceX. The company is expected to start trading next month.

Background of SpaceX

Musk founded SpaceX in 2002 with the goal of reducing space launch costs and building a colony on Mars. The company achieved its first successful space launch in 2008 and has since completed over 650 launches. SpaceX also aims to build data centers in space.

SpaceX’s relentless focus on innovation has driven its success. The company has made significant breakthroughs, including reusable orbital rockets, vertical rocket landings, and onboard autonomous systems.

SpaceX’s Path to IPO

SpaceX confidentially filed for an IPO in April and plans to disclose its prospectus soon. The company aims to start a roadshow to market the deal to investors on June 8. The filing must be disclosed at least 15 days before the roadshow begins.

The IPO is expected to be the largest ever, after SpaceX merged with xAI, Musk’s artificial intelligence company, in February. The combined entity is valued at $1.25 trillion.

Unique Channels for Retail Investors

Given the unprecedented size of this IPO, SpaceX’s advisers are exploring unique channels. They are seeking out brokers in countries like the U.K., Japan, and Canada to obtain allocations for clients.

Wall Street is eager for IPOs after a yearslong drought. Investors are particularly excited about anything tied to the AI trade. This excitement is evident as AI chipmaker Cerebras soared 68% in its debut, closing with a market cap of about $95 billion.

Market Expectations and Future Prospects

SpaceX’s filing could coincide with the 12th test flight of its next-generation Starship rocket. The company previously targeted May 19 for this test flight.

The market awaits upcoming IPOs from SpaceX, OpenAI, and Anthropic. These offerings could push their valuations past $1 trillion.

The post Spacex Ipo appeared first on The Daily Update.